After a rocky start, the $108 million Global Health Investment Fund has made its 10th investment, leading a $10 million financing for Vienna-based Themis Bioscience, which has made good progress on a vaccine for the chikungunya virus.

The health fund was established by JPMorgan Chase and the Bill & Melinda Gates Foundation to bridge a very specific gap: capital to bring to market promising late-stage drugs, vaccines and diagnostic tools for diseases that disproportionately burden low-income populations.

"Priority review vouchers” represent “a potentially lucrative source of revenue that can offset part of the development costs and provide a return on investment to funders,” according to the consulting firm Tideline in a report backed by the Gates Foundation.

Read the source article about global health investments by David Bank at ImpactAlpha